SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 3 - Initial statement of beneficial ownership of securities:
SEC Accession No. 0000905718-16-001792
Filing Date
2016-12-05
Accepted
2016-12-05 16:06:14
Documents
2
Period of Report
2016-11-29

Document Format Files

Seq Description Document Type Size
1 OWNERSHIP DOCUMENT lavalle_form3nov292016.html 3  
1 OWNERSHIP DOCUMENT lavalle_form3nov292016.xml 3 1602
2 POWER OF ATTORNEY lavalle_poa.htm EX-24 5163
  Complete submission text file 0000905718-16-001792.txt   8392
Mailing Address 53 FRONTAGE ROAD SUITE 220 HAMPTON NJ 08827
Business Address 53 FRONTAGE ROAD SUITE 220 HAMPTON NJ 08827 908-200-7500
Celldex Therapeutics, Inc. (Issuer) CIK: 0000744218 (see all company filings)

IRS No.: 133191702 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2835 In Vitro & In Vivo Diagnostic Substances

Mailing Address C/O CELLDEX THERAPEUTICS, INC. 53 FRONTAGE ROAD, SUITE 220 HAMPTON NJ 08827
Business Address
LaVallee Theresa (Reporting) CIK: 0001690948 (see all company filings)

Type: 3 | Act: 34 | File No.: 000-15006 | Film No.: 162033834